Infections and glycolipids [1]

Postgraduate Medical Journal

Volumn 79, Issue 929, 2003, Pages 185-

  Radin, N S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; GLUTATHIONE; GLYCOLIPID; GLYCOSPHINGOLIPID; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; ANTIINFECTIVE AGENT; MEMBRANE PROTEIN;

BINDING SITE; CELL SURFACE; GAUCHER DISEASE; HUMAN; INFECTION; LETTER; LIPID HYDROLYSIS; LIPID OXIDATION; PATHOGENESIS; METABOLISM; NOTE; SALMONELLOSIS;

ANTI-BACTERIAL AGENTS; GAUCHER DISEASE; GLYCOLIPIDS; GLYCOSPHINGOLIPIDS; HUMANS; MEMBRANE PROTEINS; SALMONELLA INFECTIONS;

EID: 0242499999     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.929.185     Document Type: Letter

References (5)

1. Margalit M, Ash N, Zimran A, et al. Enzyme replacement therapy in the management of longstanding skeletal and soft tissue salmonella infection in a patient with Gaucher's disease. Postgrad Med J 2002;78:564-5.
2. Svensson M, Lindstedt R, Radin NS, et al. Epithelial glucosphingolipid expression as a determinant of bacterial adherence and cytokine production. Infect Immun 1994;62:4404-10.
3. Svensson M, Frendeus B, Butters T, et al. Glycolipid depletion in antimicrobial therapy. Mol Microbiol 2003;47:453-61.
4. Hug P, Lin HM, Korte T, et al. Glucosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol 2000;74:6377-85.
5. Radin NS. Treating glucosphingolipid disorders by chemotherapy: use of approved drugs and over-the-counter remedies. J Inherit Metab Dis 2000;23:767-77.